Last $15.67 USD
Change Today +0.116 / 0.75%
Volume 6.9K
AMBI On Other Exchanges
As of 9:44 AM 10/20/14 All times are local (Market data is delayed by at least 15 minutes).

ambit biosciences corp (AMBI) Snapshot

Previous Close
Day High
Day Low
52 Week High
10/21/13 - $18.50
52 Week Low
07/16/14 - $4.80
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

ambit biosciences corp (AMBI) Related Bloomberg News

View More Bloomberg News

ambit biosciences corp (AMBI) Related Businessweek News

No Related Businessweek News Found

ambit biosciences corp (AMBI) Details

Ambit Biosciences Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of oncology, autoimmune, and inflammatory diseases in the United States. The company’s products include quizartinib, an orally administered FMS-like tyrosine kinase 3 inhibitor that has completed Phase II clinical trials for the treatment of patients with relapsed/refractory acute myeloid leukemia. Its drug candidates also comprise AC410, a small molecule inhibitor of Janus kinase 2, which is in Phase 1 clinical trials; and AC708, a receptor tyrosine kinase inhibitor that is in pre-clinical studies for the treatment of oncology, autoimmune, and inflammatory diseases. The company has collaboration agreements with Astellas Pharma Inc. to research, develop, and commercialize various FLT3 kinase inhibitors; Cephalon, Inc. to identify and develop clinical candidates that target the BRAF kinase and a second kinase; and Genoptix, Inc. to develop a laboratory diagnostic test to identify patients that harbor ITD mutations in their FLT3 receptor tyrosine kinase. Ambit Biosciences Corporation, formerly known as Aventa Biosciences Corporation, was founded in 2000 and is headquartered in San Diego, California.

53 Employees
Last Reported Date: 08/12/14
Founded in 2000

ambit biosciences corp (AMBI) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $440.1K
Chief Financial Officer and Principal Account...
Total Annual Compensation: $302.1K
Chief Medical Officer
Total Annual Compensation: $376.0K
Compensation as of Fiscal Year 2013.

ambit biosciences corp (AMBI) Key Developments

Ambit Biosciences Corporation Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014

Ambit Biosciences Corporation reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported revenues of USD 26,000 against USD 11,547,000 a year ago. Loss from operations was USD 10,557,000 against income from operations of USD 2,686,000 a year ago. Net loss was USD 8,286,000 against net income of USD 5,160,000 a year ago. The decrease in revenue of USD 11.5 million was primarily due to the termination of the company's collaboration with Astellas Pharma, effective September 2013. For the six months, the company reported revenues of USD 58,000 against USD 18,139,000 a year ago. Loss from operations was USD 20,090,000 against USD 1,503,000 a year ago. Net loss was USD 17,284,000 against USD 3,142,000 a year ago.

Ambit Biosciences Mulls Acquisitions

Ambit Biosciences Corporation (NasdaqGM:AMBI) has filed a shelf registration. Ambit Biosciences may use a portion of the net proceeds to acquire or invest in businesses, products and technologies that are complementary to our own, although we have no current plans, commitments or agreements with respect to any acquisitions as of the date of this prospectus.

Ambit Biosciences Corporation to Report Q2, 2014 Operating Results on Aug 12, 2014

Ambit Biosciences Corporation announced that they will report Q2, 2014 operating results at 5:00 PM, Eastern Standard Time on Aug 12, 2014


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AMBI:US $15.67 USD +0.116

AMBI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for AMBI.
View Industry Companies

Industry Analysis


Industry Average

Valuation AMBI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 31.0x
Price/Book 6.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 25.2x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AMBIT BIOSCIENCES CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at